Two Novel Coronavirus Omicron Inactivated Vaccines of China Biosciences Received Clinical Approval in Hong Kong

IT House news on April 18, according to the release of China Bio, recently, two new coronavirus inactivated vaccines (Omicron variant, Wuhan Institute of Biological Products) developed by Sinopharm China Bio-Beijing Institute of Biological Products and Wuhan Institute of Biological Products hereinafter referred to as “O strain”) was approved by the University of Hong Kong and the Hong Kong Island Western Hospital Cluster Research Ethics Committee of the Hospital Authority, as well as the clinical trial approval from the Hong Kong Pharmacy and Poisons Authority, and was officially approved to carry out sequential immunization of the new crown vaccine in Hong Kong clinical research.

The Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, affiliated to China Biotechnology, carried out scientific research and developed BIBP-new coronavirus inactivated vaccine (O strain) and WIBP-new coronavirus inactivated vaccine (O strain). The Omicron strain was inoculated into Vero cells, and it was made by culturing, inactivating, purifying, and adsorbing with aluminum hydroxide adjuvant.

After the successful development of the vaccine, China Biotechnology actively carried out in-depth cooperation with the University of Hong Kong, and submitted an ethical application and a clinical trial application to the Hong Kong Research Center as soon as possible, and successfully obtained the ethical approval and clinical approval on April 12 and April 13 respectively. .

In the next step, Sino Bio will use a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the new crown vaccine to evaluate the BIBP-novel coronavirus inactivated vaccine The safety and immunogenicity of two vaccines (O strain) and WIBP-novel coronavirus inactivated vaccine (O strain).